Condition: Prostate Cancer · Other Solid Tumors · Ewing Sarcoma · Sponsor: Hangzhou DAC Biotechnology Co., Ltd.
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.
This description comes directly from the study's public registry record.
Pengyu Shi, Doctor · +86-0571-56050590 · Shipengyu@dacbiotech.com
Always discuss trial participation with your own doctor first.
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Zhejiang Provincial People's Hospital | Hangzhou, Zhejiang, China | Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Peking University People's Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06926283